C
6.88
0.10 (1.47%)
| Previous Close | 6.78 |
| Open | 6.62 |
| Volume | 2,329,769 |
| Avg. Volume (3M) | 3,299,573 |
| Market Cap | 542,068,672 |
| Price / Earnings (TTM) | 3.11 |
| Price / Earnings (Forward) | 2.45 |
| Price / Sales | 2.28 |
| Price / Book | 1.43 |
| 52 Weeks Range | |
| Earnings Date | 12 Nov 2025 |
| Profit Margin | 20.81% |
| Operating Margin (TTM) | 51.49% |
| Diluted EPS (TTM) | 0.250 |
| Total Debt/Equity (MRQ) | 0.41% |
| Current Ratio (MRQ) | 4.21 |
| Operating Cash Flow (TTM) | -13.57 M |
| Levered Free Cash Flow (TTM) | -21.07 M |
| Return on Assets (TTM) | 8.31% |
| Return on Equity (TTM) | 19.87% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | CorMedix Inc. | Bearish | Bullish |
AIStockmoo Score
1.3
| Analyst Consensus | 3.0 |
| Insider Activity | 2.0 |
| Price Volatility | 4.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | -2.5 |
| Average | 1.30 |
|
Cormedix Inc is a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions. The Company’s focus is on the commercialization of its product, DefenCath, in the United States (U.S.) and other key markets. The group currently operates in a single segment, Drug Product, located in a single geographic location, the United States. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Insiders | 1.08% |
| % Held by Institutions | 34.20% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Oberweis Asset Management Inc/ | 30 Sep 2025 | 785,700 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 22.00 (RBC Capital, 219.77%) | Buy |
| Median | 16.50 (139.83%) | |
| Low | 14.00 (D. Boral Capital, 103.49%) | Buy |
| Average | 17.25 (150.73%) | |
| Total | 4 Buy | |
| Avg. Price @ Call | 9.47 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| D. Boral Capital | 08 Jan 2026 | 14.00 (103.49%) | Buy | 7.51 |
| 18 Dec 2025 | 14.00 (103.49%) | Buy | 11.92 | |
| Needham | 08 Jan 2026 | 15.00 (118.02%) | Buy | 7.51 |
| 12 Nov 2025 | 16.00 (132.56%) | Buy | 11.42 | |
| HC Wainwright & Co. | 13 Nov 2025 | 18.00 (161.63%) | Buy | 11.21 |
| RBC Capital | 21 Oct 2025 | 22.00 (219.77%) | Buy | 11.65 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| HURLBURT ELIZABETH | - | 7.15 | -5,794 | -41,427 |
| LEFKOWITZ STEVEN W | - | - | 0 | 0 |
| SECKLER MICHAEL DAVID | 7.51 | - | 133,156 | 1,000,002 |
| TODISCO JOSEPH | - | 6.97 | -40,082 | -278,200 |
| Aggregate Net Quantity | 87,280 | |||
| Aggregate Net Value ($) | 680,374 | |||
| Aggregate Avg. Buy ($) | 7.51 | |||
| Aggregate Avg. Sell ($) | 7.03 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| TODISCO JOSEPH | Officer | 17 Jan 2026 | Disposed (-) | 22,665 | 6.78 | 153,669 |
| TODISCO JOSEPH | Officer | 16 Jan 2026 | Option execute | 29,585 | - | - |
| LEFKOWITZ STEVEN W | Director | 12 Jan 2026 | Option execute | 15,000 | - | - |
| TODISCO JOSEPH | Officer | 12 Jan 2026 | Disposed (-) | 17,417 | 7.15 | 124,532 |
| HURLBURT ELIZABETH | Officer | 12 Jan 2026 | Disposed (-) | 5,794 | 7.15 | 41,427 |
| SECKLER MICHAEL DAVID | Officer | 08 Jan 2026 | Acquired (+) | 133,156 | 7.51 | 1,000,002 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |